Breast cancer, neoadjuvant chemotherapy, tumour response evaluation
Conditions
Interventions
Performing a three-dimensional ultrasonography in addition to the breast MRI (standard of care) to evaluate the tumour response during neoadjuvant chemotherapy in breast cancer patients. The three-di
Sponsors
Erasmus Medical Centre, Cancer Institute
Erasmus Medical Centre, Department of Surgery
Eligibility
Inclusion criteria
Inclusion criteria: Female Aged > 18 year Adenocarcinoma of the breast visible on ultrasonography
Exclusion criteria
Exclusion criteria: T4 breast cancer stadium (i.e. tumor of any size growing in to the chest wall or skin)
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Concordance between longest tumour diameter during response evaluation. Longest diameter will be accessed and compared between the (conventional) MRI and the ABVS. | — |
Secondary
| Measure | Time frame |
|---|---|
| 1) The concordance of volume (instead of longest diameter) response evaluation of the (conventional) MRI and the ABVS; 2) The diagnostic accuracy of the ABVS to predict a pathologic complete response; 3) Patients preferences as measured by a questionnaire; 4) The costs of the response evaluation by the (conventional) MRI as compared to the ABVS. | — |
Contacts
Public ContactL.B. Koppert,
Department of Surgery, Erasmus MC Cancer Institute PO Box 5201
Outcome results
None listed